A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Doxorubicin|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: Trastuzumab
Sponsor: Hoffmann-La Roche